Effect of rectal cancer treatment on tumor cells in blood
Part of Cancer clinical trials.
This study looks at how different treatments for rectal cancer affect tumor cells that travel in your blood. It is an observational study, meaning you will not receive any new treatment, but your blood will be tested to help doctors learn more.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rectal cancer
- You do not have any other type of cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying a blood test (CTC) for people with rectal cancer that hasn't spread to other parts of the body. It aims to see how the test relates to treatment outcomes after surgery.
This study looks at the long-term effects of rectal cancer treatment on gynecological and sexual health. It aims to understand how women recover after treatment, helping improve future care and support.
This study looks at tissue samples from people who had surgery for rectal cancer to learn more about the disease. It may help improve future treatments.
This trial is looking at whether a simple blood test (ctDNA monitoring) can help predict how well total neoadjuvant therapy (chemo and radiation before surgery) works for rectal cancer. It may help doctors tailor treatment to your specific needs.
This study looks at whether a blood test that finds tumor DNA can help doctors choose the best treatment for rectal cancer, possibly allowing some patients to avoid surgery. It tests different chemotherapy and radiation combinations to see if the cancer disappears completely.
This study compares different treatments for rectal cancer to see how they affect bowel and anal function after treatment. It may help you maintain better control over your bowel movements.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.